ResMed reported a strong first quarter of calendar year 2026 (Q1 FY2026) with revenue of USD 1,335.6 million, up 9.07% year over year and a slight QoQ decline of 0.92%. The company posted a gross profit of USD 820.8 million and a gross margin of 61.46%, delivering an operating income of USD 446.5 million and an operating margin of 33.43%. Net income reached USD 348.5 million for the quarter, translating to a net margin of 26.10%. EBITDA stood at USD 446.5 million, yielding an EBITDA margin of 33.43%. The quarter showcased resilient profitability alongside a robust liquidity position, as the company maintained USD 1.384 billion in cash and equivalents and reported a net debt position of negative USD 537.5 million (i.e., net cash). Free cash flow amounted to USD 414.4 million, underscoring strong cash generation even after USD 150.0 million of share repurchases and USD 87.8 million in dividends in the period.